NCT05154630 - Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

June 30, 2023

Conditions

Advanced CancerAdvanced Soft-tissue Sarcoma

Interventions

DRUG

TQB2858 injection

TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.

Trial Locations (5)

Beijing Jishuitan Hospital, Beijing

Peking University People's Hospital, Beijing

Beijing Cancer Hospital, Beijing

Peking University Shougang Hospital, Beijing

West China Hospital，Sichuan University, Chengdu